Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Nov 20, 2020 11:20pm
139 Views
Post# 31946183

RE:RE:RE:RE:RE:RE:RE:Warrant revaluation

RE:RE:RE:RE:RE:RE:RE:Warrant revaluationMy bad, I left out the change in value of the convertable debentures, it's not a true loss the same as warrant liabilities so it isn't required, but thats a story for another day. doesn't change the math below. night folks....except olteanu lol

Jonnyboy85 wrote: Sorry, I was mixing up two concepts, I was on a train of thought related to assets (will post about that soon:) when I replied. What I can tell you about the revenue calculation was that you can completely remove revaluations of warrant liabilities ( it's arbitrary and represents little to no cost to the company, in fact we make money from them), and you can remove $404,560 of share based compensation, it actually makes us money when they are excersized, somewhat in the same way warrants make us money as well, though again both are dilutive. You can also leave out depreciation (-72,537), because it's not a cost per se, but it does help us on our taxes lol


So remove those two and you have,


Total revenues +1,464,155
Cost of goods sold -973,502 
General and administrative  -1,181,580   [1,181,580 - $404,560 ( share based compensation)]
General and administrative recalculated removing share based compensation -777,020
Finance costs  -103,468


So realistically we near broke even on our operating costs versus revenue. 
$1,464,155 revenue  -  1,853,990 costs = 389,835 loss which is under a penny per share:)


So the moral of the story is we have a lot of "losses" that aren't real losses, in fact most of them will end up being very valuable to us, but they have to be accounted for somewhere and because they are technically debts, on paper they count against our revenue.
 
MSmitty2020 wrote: Buying inventory of supplies does not get expenses it is inventory on the balance sheet as an asset until it is consumed then it gets expensed so that logic doesn't work for me ... unless they are not putting supplies to inventory in which case perhaps they should 




<< Previous
Bullboard Posts
Next >>